TAT-PiET 

TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET can be used for the research of cancer, such as breast cancer^[1].

TAT-PiET inhibits proliferation in MCF7, T47D, MDA-MB231, and BT549 cell with EC₅₀ values of 8.13, 13.35, 4.68 and 32.34 μM^[1].
TAT-PiET (10 μM) inhibits colony formations in MCF7 and MDA-MB231 cells TAT-PiET (10 μM) inhibits migration in MCF7 and MDA-MB231 cells TAT-PiET (10 μM, 6 h) decreases expression of c-Myc, N-myc, and CCND1 in MCF7 and MDA-MB-231 cells TAT-PiET (10 μM) increases sensitivities in Tamoxifen (HY-13757A) -resistant MCF7 and T47Dcells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TAT-PiET (25 mg/kg, i.p., every 2 days) inhibits tumor growth in MCF/MDA-MB2317 tumor mice models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2651.07

C₁₁₀H₁₉₂N₄₈O₂₇S

3036046-03-1

Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Arg-Asn-Gln-Lys-Phe-Lys-Cys-Gly-Glu

YGRKKRRQRRRRNQKFKCGE

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Huang QX, et al. Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo. J Med Chem. 2024 Apr 25;67(8):6658-6672.  [Content Brief]